Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis

BACKGROUND: Purine nucleoside analogs (PNAs) are the recommended first-line treatment for patients with hairy cell leukemia (HCL), but they are associated with adverse events (AEs). Due to a lack of real-world evidence regarding AEs that are associated with PNAs, we used commercial data to assess AE...

Descripción completa

Detalles Bibliográficos
Autores principales: Epperla, Narendranath, Pavilack, Melissa, Olufade, Temitope, Bashyal, Richa, Li, Jieni, Kabadi, Shaum M., Yuce, Huseyin, Andritsos, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020358/
https://www.ncbi.nlm.nih.gov/pubmed/32054500
http://dx.doi.org/10.1186/s13023-020-1325-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020358/
https://www.ncbi.nlm.nih.gov/pubmed/32054500
http://dx.doi.org/10.1186/s13023-020-1325-9

Ejemplares similares